Patient and disease characteristics (n=2740)
| n | % | |
| Age at diagnosis | ||
| Median (mean) | 45 (43.8) | |
| Range | 20–60 | |
| IQR | 40–48 | |
| Year of diagnosis | ||
| 2010 | 530 | 19.3 |
| 2011 | 537 | 19.6 |
| 2012 | 498 | 18.2 |
| 2013 | 597 | 21.8 |
| 2014 | 578 | 21.1 |
| Family history* | ||
| No | 1218 | 45.7 |
| Yes | 1445 | 54.3 |
| Unknown | 77 | |
| Live children | ||
| No | 749 | 27.3 |
| Yes | 1991 | 72.7 |
| Histology | ||
| Any ductal no lobular | 2188 | 79.9 |
| Any lobular no ductal | 268 | 9.8 |
| Lobular and ductal | 176 | 6.4 |
| Inflammatory | 12 | 0.4 |
| Other | 96 | 3.5 |
| Grade* | ||
| G1 | 196 | 7.8 |
| G2 | 631 | 25.0 |
| G3 | 1694 | 67.2 |
| Unknown | 219 | |
| LN pos exact* | ||
| No | 1746 | 63.8 |
| Yes | 991 | 36.2 |
| Unknown | 3 | |
| Stage* | ||
| I | 1377 | 54.4 |
| II | 846 | 33.4 |
| III | 307 | 12.2 |
| Unknown | 210 | |
| Chemotherapy | ||
| No | 1020 | 37.2 |
| Yes | 1720 | 62.8 |
| HER-2 targeted therapy | ||
| None | 2306 | 84.2 |
| Trastuzumab | 328 | 12.0 |
| Trastuzumab+other | 106 | 3.9 |
| Any endocrine treatment | ||
| No | 213 | 7.8 |
| Yes | 2527 | 92.2 |
| BSO | ||
| None | 2506 | 91.5 |
| Yes | 234 | 8.5 |
| Medical OS | ||
| None | 2458 | 89.7 |
| Yes | 282 | 10.3 |
*For these variables, the unknowns are not considered in the percentage reporting.
BSO, bilateral salpingo-oophorectomy; HER-2, human epidermal growth factor receptor 2; IQR, interquartile range; LN, lymph node; OS, ovarian suppression.